Sarah Boyce, the President and CEO of $RNA, sold 25,000 shares of the company on 08-28-2025 for an estimated $1,234,700. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.6% of their shares of this class of stock. Following this trade, they now own 305,871 shares of this class of $RNA stock.
$RNA Insider Trading Activity
$RNA insiders have traded $RNA stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $RNA stock by insiders over the last 6 months:
- ERIC MOSBROOKER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 130,807 shares for an estimated $5,763,696.
- ARTHUR A LEVIN sold 107,500 shares for an estimated $5,118,881
- TROY EDWARD WILSON has made 0 purchases and 6 sales selling 95,054 shares for an estimated $4,277,430.
- STEVEN GEORGE HUGHES (Chief Medical Officer) has made 0 purchases and 8 sales selling 94,762 shares for an estimated $3,952,171.
- SARAH BOYCE (President and CEO) has made 0 purchases and 2 sales selling 56,540 shares for an estimated $2,214,263.
- W. MICHAEL FLANAGAN (Chief Scientific Officer) has made 0 purchases and 3 sales selling 51,780 shares for an estimated $1,626,175.
- MICHAEL F MACLEAN (Chief Financial Officer) has made 0 purchases and 2 sales selling 38,849 shares for an estimated $1,567,268.
- KATHLEEN P. GALLAGHER (Chief Program Officer) has made 0 purchases and 6 sales selling 24,411 shares for an estimated $744,998.
- TERESA MCCARTHY (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 17,778 shares for an estimated $707,215.
- JOHN B MORIARTY (Chief Legal Officer) sold 2,245 shares for an estimated $81,291
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RNA Hedge Fund Activity
We have seen 113 institutional investors add shares of $RNA stock to their portfolio, and 148 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK added 3,532,825 shares (+inf%) to their portfolio in Q2 2025, for an estimated $100,332,230
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 1,270,931 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $36,094,440
- RA CAPITAL MANAGEMENT, L.P. added 965,623 shares (+15.3%) to their portfolio in Q2 2025, for an estimated $27,423,693
- RTW INVESTMENTS, LP added 871,919 shares (+10.0%) to their portfolio in Q2 2025, for an estimated $24,762,499
- BOXER CAPITAL MANAGEMENT, LLC removed 865,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $24,566,000
- JANUS HENDERSON GROUP PLC removed 649,379 shares (-5.7%) from their portfolio in Q2 2025, for an estimated $18,442,363
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 618,881 shares (-28.8%) from their portfolio in Q2 2025, for an estimated $17,576,220
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RNA Analyst Ratings
Wall Street analysts have issued reports on $RNA in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 08/08/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- Goldman Sachs issued a "Buy" rating on 07/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/27/2025
- Wolfe Research issued a "Outperform" rating on 06/17/2025
- Raymond James issued a "Strong Buy" rating on 06/11/2025
- Citigroup issued a "Buy" rating on 06/10/2025
To track analyst ratings and price targets for $RNA, check out Quiver Quantitative's $RNA forecast page.
$RNA Price Targets
Multiple analysts have issued price targets for $RNA recently. We have seen 13 analysts offer price targets for $RNA in the last 6 months, with a median target of $68.0.
Here are some recent targets:
- Yanan Zhu from Wells Fargo set a target price of $75.0 on 08/08/2025
- Gena Wang from Barclays set a target price of $62.0 on 08/08/2025
- Keay Nakae from Chardan Capital set a target price of $75.0 on 08/08/2025
- Corinne Johnson from Goldman Sachs set a target price of $55.0 on 07/10/2025
- Eric Schmidt from Cantor Fitzgerald set a target price of $96.0 on 06/27/2025
- Andy Chen from Wolfe Research set a target price of $55.0 on 06/17/2025
- Michael Freeman from Raymond James set a target price of $65.0 on 06/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
